Cytokinetics Analyst Ratings
JP Morgan Maintains Overweight on Cytokinetics, Lowers Price Target to $65
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $90 Price Target
Cytokinetics Analyst Ratings
Cytokinetics Analyst Ratings
J.P. Morgan Securities: Reiterates the Cytokinetics (CYTK.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $78.00 to $78.00.
Cytokinetics Analyst Ratings
JMP Securities Reiterates Market Outperform on Cytokinetics, Maintains $78 Price Target
Analysts Conflicted on These Healthcare Names: Cytokinetics (CYTK) and Canopy Growth (CGC)
Truist Financial Sticks to Its Buy Rating for Cytokinetics (CYTK)
Cytokinetics Inc.: Truist Securities cuts price target from $86 to $70
JMP Securities Maintains Market Outperform on Cytokinetics, Lowers Price Target to $78
J.P. Morgan Securities: Maintaining the Cytokinetics (CYTK.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $106.00 to $78.00.
Cytokinetics Analyst Ratings
Buy Rating Justified for Cytokinetics Amid Strong Capital Position and Promising Drug Pipeline
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Medtronic (MDT) and Cytokinetics (CYTK)
Raymond James Adjusts Price Target on Cytokinetics to $70 From $92, Maintains Outperform Rating
Cytokinetics: Strong Buy Rating Backed by Significant Financial Support and Promising Pipeline
Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Soleno Therapeutics (SLNO)
Needham Maintains Buy on Cytokinetics, Lowers Price Target to $72